DTU Logo
Publications | Conference abstracts | Slidesets | Webcasts

Publications (18 of 433)

Search Publications :


Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes - Authors' reply
Rury R. Holman, Eric D. Peterson
N Eng J Med 2015;373:2479. Published:17-Dec-2015. PMID:26672857. doi:10.1056/NEJMc1510995

Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study
David Preiss, Laine E Thomas, Daniel M Wojdyla, Steven M Haffner, Jason M R Gill, Thomas Yates, Melanie J Davies, Rury R Holman, John J McMurray, Robert M Califf, William E Kraus, on behalf of the NAVIGATOR investigators
BMJ Open 2015;5:e007901. Published:11-Nov-2015. Epub:14-Aug-2015. PMID:26275900. doi:10.1136/bmjopen-2015-007901

Cardiovascular outcome trials of glucose-lowering drugs in type 2 diabetes: 10 frequently asked questions
Jyothis George
Practical Diabetes 2015;32:301-304. Published:Oct-2015. Epub:16-Oct-2015. doi:10.1002/pdi.1976

GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.
Michael J. Theodorakis
Diabetes 2015;64:e28-e29. Published:Sep-2015. Epub:01-Sep-2015. PMID:26294437. doi:10.2337/db15-0614

Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial
T. Yates, M. J. Davies, S. M. Haffner, P. J. Schulte, L. Thomas, K. M. Huffman, C. W. Bales, D. Preiss, R. M. Califf, R. R. Holman, J. J. V. McMurray, M. A. Bethel, J. Tuomilehto and W. E. Kraus
Diabetic Medicine 2015;32:1090-1096. Published:Aug-2015. Epub:12-Apr-2015. PMID:25818859. doi:10.1111/dme.12762

Physiology of GNRH and Gonadotropin Secretion
Pedro Marques, Karolina Skorupskaite, Kavitha S. Rozario, Richard A. Anderson and Jyothis T. George
Endotext 2015;1:1-30. Published:31-Jul-2015. PMID:25905297

Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice
Carla Francés Artigas, Victoria Stokes, Garry D Tan and Michael J Theodorakis
Expert Opin. Pharmacother. 2015;16:1417-1421. Published:17-Jul-2015. Epub:16-Jun-2015. PMID:26077113. doi:10.1517/14656566.2015.1052740

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, Keith D. Kaufman, Joerg Koglin, Scott Korn, John M. Lachin, Darren K. McGuire, Michael J. Pencina, Eberhard Standl, Peter P. Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
N Engl J Med 2015;373:232-242. Published:16-Jul-2015. Epub:08-Jun-2015. PMID:26052984. doi:10.1056/NEJMoa1501352
Erratum in :
N Engl J Med 201;373:586, Print:06-Aug-2015, Epub:16-Jul-2015, PMID:26182233, doi:10.1056/NEJMx150029

The University of Oxford Diabetes Trials Unit
Mark Nicholls, Rury Holman
European Heart Journal 2015;36:1706-07. Published:14-Jul-2015. PMID:26393241

Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD
Jonathan C. Levy, Axel Riefflin & Rury R. Holman
Diabetologia 2015;58:1376-7. Published:Jun-2015. Epub:26-Mar-2015. PMID:25810041. doi:10.1007/s00125-015-3574-z

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial [Chinese Abstract]
Hu Da Yi, Pan Chang Yu, Rury R. Holman.
Chinese Journal of Cardiology 2015;43:412. Published:24-May-2015. doi:10.3760/cma.j.issn.0253-3758.2015.05.008

How does obesity affect fertility in men - and what are the treatment options?
Victoria J. Stokes, Richard A. Anderson and Jyothis T. George
Clinical Endocrinology 2015;82:633-8. Published:May-2015. Epub:16-Sep-2014. PMID:25138694. doi:10.1111/cen.12591

Normal weight individuals with type 2 diabetes: The Personal Fat Threshold
Roy Taylor and Rury R. Holman
Clinical Science 2015;128:405-410. Published:01-Apr-2015. PMID:25515001. doi:10.1042/CS20140553

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M. A. Bethel, J. B. Green, J.Milton, A.Tajar, S.S.Engel, R.M.Califf, R.R.Holman on behalf of the TECOS Executive Committee
Diabetes, Obesity and Metabolism 2015;17:395-402. Published:Apr-2015. Epub:13-Feb-2015. PMID:25600421. doi:10.1111/dom.12441

The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)
M. L. Alva, A. Gray, B. Mihaylova, J. Leal and R. R. Holman
Diabetic Medicine 2015;32:459-466. Published:Apr-2015. Epub:07-Jan-2015. PMID:25439048. doi:10.1111/dme.12647

Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials
The Blood Pressure Lowering Treatment Trialists’ Collaboration
Lancet 2015;385:867-74. Published:07-Mar-2015. Epub:04-Nov-2014. PMID:25468168. doi:10.1016/S0140-6736(14)61171-5

Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
M. A. Bethel, W. Xu, M. J. Theodorakis
Diabetes, Obesity and Metabolism 2015;17:231-244. Published:Mar-2015. Epub:27-Nov-2014. PMID:25312701. doi:10.1111/dom.12401

The effect of glibenclamide on insulin secretion at normal glucose concentrations
Axel Riefflin, Usha Ayyagari, Susan E. Manley, Rury R. Holman, Jonathan C. Levy
Diabetologia 2015;58:43-49. Published:Jan-2015. Epub:09-Oct-2014. PMID:25297572. doi:10.1007/s00125-014-3399-1